Correction to Janssen Breakthrough Therapy Designation Story
March 10 2020 - 6:51PM
Dow Jones News
The U.S. Food and Drug Administration had granted Breakthrough
Therapy Designation for JNJ-61186372 to treat certain patients with
non-small-cell lung cancer. "Janssen Says FDA Grants Breakthrough
Therapy Designation to JNJ-6372 to Treat Lung Cancer," at 4:27 p.m.
EDT, incorrectly reported that it was for the treatment of certain
patients with small-cell lung cancer in the first paragraph.
(END) Dow Jones Newswires
March 10, 2020 18:36 ET (22:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024